Metabolomics Global Market Size Scope of the Study This report gives an insight into Metabolomics Technologies – Combined/Integrated Systems, Hardware Systems for metabolic analytics and Software Systems. Though the report mentions about non-medical applications of metabolomics, the study emphasizes only on the medical applications. The study includes estimates and projections for the total global metabolomics market. Projections and estimates are also illustrated by geographic region including the United States, Europe, Japan, Asia-Pacific, Canada and Rest of World. Business profiles of 29 major companies are discussed in the report. The report serves as a guide to global metabolomics industry, covering more than 250 companies that are engaged in metabolomics R&D and supply of products and services. Major Contract Research Organizations and Universities serving metabolomics industry are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report. Metabolomics report is an ideal research tool providing strategic business intelligence to the corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies, contract research organizations, biotechnology companies and drug approval authorities in- Gauging Competitive Intelligence Identifying Key Growth Areas and Opportunities Understanding Geographic Relevance to Product Knowing Regional Market Sizes and Growth Opportunities and Restraints Keeping Tab on Emerging Technologies Equity Analysis Tapping New Markets
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 1
Analytics and data presented in this report pertain to several parameters such as – Global And Regional Market Sizes, Market Shares, Market Trends Product (Global And Regional) Market Sizes, Market Shares, Market Trends Technology Trends Corporate Intelligence Key Companies By Sales, Brands, Products Consumer Behavioral Patterns Other Strategic Business Affecting Data
Research Methodology RI Technologies publishes business intelligence reports by going through a cycle of diligent research and analysis activity. Research is done using both online and offline resources. The study outline of this report is sketched on the following lines – global market analysis, regional market analysis, product segmentation, global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape, technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is also helpful for doing market evaluations, and estimating the market size for the future.
This report is uniquely researched and the methodology includes: Need and Scope of Study Product Definitions Segmental Analysis Regional Analysis Exclusive Data Analytics Corporate Intelligence Feedback
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 2
Right from concept to final compilation of this report, both primary and secondary research methods are applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the information for authentication of our own findings. Secondary research includes government publications, investment research reports, web based surveys, website information of both companies and markets, and other offline resources such as print publications and CDs. Our compilation of easy to navigate PDF reports are essential value addition resources for leading and growing companies.
RITMIR004: Metabolomics – A Market Insight Report, July 2013 Š RI Technologies - www.researchimpact.com
Sample Page - 3
II. REPORT SYNOPSIS
The decoding of the human genome produced two distinct studies popularly called genomics and proteomics that deal with the aspects of genes and proteins respectively and are said to possess extensive clinical potential. In the presence of these two"-omics” studies, a new study has emerged that is believed to provide cost effective, quick and effectual methods of disease diagnosis and facilitates effective monitoring of administered therapies in patients - Metabolomics. The study of metabolite profiles in biofluids and biological samples such as blood plasma, saliva, and urine is termed as Metabolomics. Metabolites are the by-products or the residues of metabolism. Metabolism can be defined as the process of transformation of food energy into mechanical energy or heat energy, which is an increasing area of interest for research scientists. The varieties of metabolites present in the human body range from 2,500-3,000 and sometimes as high as 20,000. This is observed to be very low when compared with the range of 29,000, and 100,000 of genes and proteins respectively. The area of interest of scientific researchers is particularly in the small low-molecular-weight compounds of metabolomics that act as substrates and products in numerous metabolic pathways. These molecules, termed as “small molecules”, include compounds such as amino acids, sugars, and lipids that offer prominent clues about an individual's health conditions. The Metabolome, regarded as the collection of metabolites in a cell at a given point of time, is an indicator of the cell's physiological state during sampling. The human body consists of billions of cells of different varieties, with potentially diverse metabolomes. The genes and proteins present in the cell are responsible for varied responses such as cell signaling, energy transfer, and cell-to-cell communication usually regulated by metabolites. The gene and protein expression are closely related and metabolite expressions closely reflect the actual cellular environment that is governed by pollutant exposures, drug, nutrition, and other exogenous factors, which influence health. Genomics and proteomics studies indicate what may happen, where as metabolomics indicate what actually did happen. Prominent among the tools being used for metabolomic research are mass spectrometry (MS) and nuclear magnetic resonance (NMR). The data thus collected is then analyzed by appropriate bioinformatics suites. Most of the tools used for metabolomic research are already in use, though their sensitivity and sophistication continues to be refined. High-throughput methods such as nuclear magnetic resonance (NMR) spectroscopy and mass spectroscopy (MS) using robotic automation are used for data collection in metabolomics.
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 4
This can be regarded as an excellent tool for quick collection of vast amount of information pertaining to molecular composition in a given sample. When an individual is affected with a disease, his/her metabolism gets affected and this change in metabolism can be utilized as an indicator for treatment of the same. The reputation of metabolomics research activities is gaining prominence day by day. Several institutes and research centers in the field of metabolomics are cropping up to explore the possibilities in the field of Metabolism and Structural Biology. These research organizations aim at bringing people from various fields in a single platform with an ultimate goal of developing metabolomics technology and integrating metabolomics with the broader universe of systems biology. Metabolite flux analysis, metabolic profiling, and biochemical modeling are some important activities in metabolomics research. Research in the industry is also on an upswing owing to the enthusiasm of pharmaceutical and biotechnology companies. They are mainly concentrating on the application of metabolite profiles as potential tools for drug discovery. The process of applying the tools of metabolite analysis (NMR and MS) to evaluate metabolite variations in biofluids is underway. This report analyzes metabolomics technologies – Combined/Integrated Systems, Hardware Systems and Software Systems. Synopsis chapter of the report gives the summary of global market by metabolomics technologies at global level and for each geographic region - North America, Europe, Asia-Pacific and Rest of World.
Segmentation of Metabolomics Technologies Drastic mutations in low molecular weight compounds, requires more than a single technique for metabolomics analysis. Traditionally, mass spectrometry and nuclear magnetic resonance are the two major platforms used for the study of metabolomics. Metabolomic technologies can be broadly divided into three major categories – Combined/Integrated Systems, Metabolomic Hardware Equipment or Hardware Systems and Metabolomic Software or Software Systems. The above categories of metabolomic technologies comprise the following technologies:
Mass Spectrometry
Nuclear Magnetic Resonance
Liquid Chromatography/Gas Chromatography
High Performance Liquid Chromatography
Lab-on-a-Chip
Capillary Electrophoresis
Electrochemical Array
Fourier-Transform Infrared Spectroscopy
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 5
Global Market Analysis Global metabolomics market is projected to reach about US$ XX.XX billion by 2020 from an estimated US$ XX.XX million in 2012, growing at compounded annual growth rate (CAGR) of XX.XX % during the analysis period 2005-2020.
Exhibit 1. Metabolomics – Global Value Market Estimations & Predictions (2005-2020) in US$ Million
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 6
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 7
III. MARKET DYNAMICS
Analysis by Metabolomics Technologies Combined Systems – The Fastest Growing Technology Combined systems refer to the integration of metabolomics hardware equipment with metabolomics software. This technology is poised to register the highest growth rate and is expected to emerge as the largest technology for metabolomics study during the period 2005-2020.
Market Analysis Global market for combined (integration of hardware and software) metabolomics systems is projected to reach US$ XX.XX billion by 2020 from an estimated US$ XX.XX million in 2012, registering a robust CAGR of XX.XX % during the analysis period 2005-2020. The United States combined metabolomics market was estimated at US$ XX.XX million in 2012 and is expected to reach about US$ XX.XX million to account for the largest market share of XX.XX % in 2020. Growing at a CAGR of XX.XX % during the period 2005-2020, the US is further projected to retain the leading position with market worth US$ XX.XX million by the year 2020.
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 8
Exhibit 2. Combined Systems* of Metabolomics– Global Value Market Estimations & Predictions (2005-2020) by Geographic Region for United States, Europe, Japan, Asia-Pacific^, Canada and Rest of World in US$ Million
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 9
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 10
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 11
METABOLOMICS – THE OUTLOOK For the past few years, the most commonly used methodologies in systems biology for exploring drug discovery have been genomics and proteomics. Now, metabolomics complements these two methods offering scientists a powerful tool that can uncover enormous amounts of information. The main difference between genomics/proteomics and metabolomics is that while the earlier methods studied genes and proteins, metabolomics focuses on metabolites, which are the substrates and end products of enzymatic reactions. Metabolites are compounds of low molecular weight, which determine the unique characteristics (phenotype) of an organism. This facilitates the identification of specific biological conditions, whether they are healthy or diseased. While work on detecting and quantifying several metabolites has been continuing for decades, it is only now that scientists are able to compile a complete metabolic profile of an organism. Today research in metabolomics is directed at tracing out specific metabolites corresponding with specific disease states to facilitate drug development. Metabolomics will make a significant impact in
Development of tools and methodology for research
Bioinformatics and software to facilitate collection and analysis of data
Pharmaceutical organizations involved in drug discovery and development
Global metabolomics market is projected to grow at XX.XX % compounded annually from 2005 through 2020. While metabolomics is a rapidly growing area, the baseline is small. Major pharmaceutical companies have been comparatively slow to adopt it, as against the wide use of genomics and proteomics. There are fears about genomics and proteomics leaving many questions unanswered and, hence, the skepticism about metabolomics is also the same. Increasing use of technology is winning over many skeptics, and widespread use of metabolomics will happen only after high profile successes. The United States, currently the leading market (expected to account for XX.XX % of global market share in 2012) for metabolomics, is projected to manage the leading position throughout the analysis period though its market share may drop to about XX.XX % by 2020. Due to the cost advantage and access to the latest technology, Asia-Pacific is emerging as the fastest growing (XX.XX % during 2005-2020) market for metabolomics. Europe and Japan are expected to gain market shares while the US may lose market dominance during the same analysis period. European metabolomics market is expected to experience a robust growth of XX.XX %, compounded annually, for the above analysis period. Currently, the European market is largely led by Germany and the UK and this trend is projected to remain the same by end of the analysis period.
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 12
Though metabolomics is still in evolution stage, biotechnology and/or pharmaceutical industry is expected to apply this technology more intensely in the near future. Metabolomics advantage is expected to provide effective results throughput the drug discovery and development process – the discovery, pre-clinical development, clinical trials and post market drug monitoring stages….
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 13
IV. PRODUCT/TECHNOLOGY RESEARCH
Backdrop The term ‘Metabolomics’ refers to a systematic study of the unique chemical fingerprints made by specific cellular processes within an organism. More particularly, it is the study of their small-molecule metabolite profiles. The collection of all metabolites in a biological organism is known as the Metabolome, which is the result of its gene expression. The term Metabolome is used to define a complete set of small-molecule metabolites that are found within a single organism. Metabolic profiling offers a quick sneak preview of the whole structure and functioning of a cell, unlike mRNA gene expression data and proteomic analyses. Integrating proteomic, transcriptomic, and metabolomic matter to make a clear picture of a living organism is one of the objectives of systems biology. The other related ‘omics’ - Metabolomics - is used in reference to drug toxicity assessment. While some investigators also use the term metabolomics, the term metabolomics has gained greater usage. The choice of a specific term is really not an indication of the specific nature of the analysis; it is simply a matter of common usage. However, metabolomics has more to do with NMR spectroscopy, while metabolomics focuses more on mass spectrometry based methodologies. It is now accepted that metabolomics refers to a wide range of metabolic changes due to biological factors, while metabolomics concerns itself more with comprehensive metabolic profiling. Often the words metabolomics and metabolomics are used interchangeably, especially in North America. It was Dr. Jeremy Nicholson, of Metabometrix Ltd., from London who coined the word metabolomics. While scientists have yet to define the two terms clearly, it is generally assumed that metabolomics research is more cell-oriented, while metabolomics concerns itself more with system-based research. However, in Europe it is metabolomics that has been the main focus of research, with emphasis on the complete set of metabolites in plants, known as metabolomes. In North America, metabolomics is slowly but surely becoming a vital component of the process of drug development and the development of better diagnostic tools. An organism’s physiology, genotype, what it eats and how it breathes are all closely linked to the Metabolome. This gives scientists a wonderful chance to study the relationships between genotype and phenotype as well as the genotype and the environment. Just as a genome or proteome, the Metabolome is a total complement of the metabolites in an organism.
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 14
Metabolomics was primarily defined as the study of metabolic profiles of biofluids in complete organisms. It was considered responsible for studying the various effects on cellular metabolomes. Metabolomics is complementary to genomics and proteomics. During recent times, metabolomics has assumed utmost importance. Few scientists are of the opinion that metabolomics is a part of metabolomics. Metabolomics is considered to include activities such as sample classification, biomarker detection, creating an understanding of biochemical mechanism, quantitative analysis of concentrations, fluxes, and probing interactions of molecular dynamics. The difference of opinion pertaining to the two terms still persists. The dilemma over the terms and the responsibility of identifying the correct terminology is being probed into by the Metabolomics Society.
Exhibit 3. Reported Frequencies of Organ Transplantations (2008): Percentage Breakdown of Frequencies for Kidney, Liver, Heart, Pancreas and Lung Transplantations
RITMIR004: Metabolomics – A Market Insight Report, July 2013 Š RI Technologies - www.researchimpact.com
Sample Page - 15
About RI Technologies RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging technologies in areas of discovery, design and development.
Research – As Good as the Methodology is!
Gauging Competitive Intelligence
Identifying Key Growth Areas and Opportunities
Understanding Geographic Relevance to Product
Knowing Regional Market Sizes and Growth Opportunities and Restraints
Keeping Tab on Emerging Technologies
Equity Analysis
Tapping New Markets
© COPYRIGHT The copyright and publication rights to all RI Technologies' reports and other products are the property of the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of the material without express permission is not allowed. The buyer, under no circumstances, shall license, resell or repackage, or sell data without prior permission of the company.
DISCLAIMER RI Technologies sells content in good faith. The company is not liable to the buyer for any implications arising out of the usage of data for any particular purpose. The company makes no representations or warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for data compilation and presentation, the company does not accept any responsibility for findings in the study which are a cumulative effort of primary and secondary research resources. The studies do not endorse or promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are not liable for inaccuracies or
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 16
incompleteness of the reports. User discretion is recommended for the usage of the data.
RITMIR004: Metabolomics – A Market Insight Report, July 2013 Š RI Technologies - www.researchimpact.com
Sample Page - 17
RITMIR004: Metabolomics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 18